Joon Kim - OncoSec Medical Director
| ONCSDelisted Stock | USD 0.0002 0.00 0.00% |
Director
Mr. Joon Kim is Director of the company. Prior to joining Lee Ko, Mr. Kim worked for several years as a litigation lawyer and served from 2008 to 2017 as a public prosecutor in California since 2018.
| Tenure | 6 years |
| Phone | 855 662 6732 |
| Web | https://oncosec.com |
OncoSec Medical Management Efficiency
The company has return on total asset (ROA) of (0.9284) % which means that it has lost $0.9284 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (4.1017) %, meaning that it created substantial loss on money invested by shareholders. OncoSec Medical's management efficiency ratios could be used to measure how well OncoSec Medical manages its routine affairs as well as how well it operates its assets and liabilities.The company currently holds 6.17 M in liabilities with Debt to Equity (D/E) ratio of 0.76, which is about average as compared to similar companies. OncoSec Medical has a current ratio of 4.42, suggesting that it is liquid enough and is able to pay its financial obligations when due. Debt can assist OncoSec Medical until it has trouble settling it off, either with new capital or with free cash flow. So, OncoSec Medical's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like OncoSec Medical sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for OncoSec to invest in growth at high rates of return. When we think about OncoSec Medical's use of debt, we should always consider it together with cash and equity.
Similar Executives
| Found 6 records | DIRECTOR Age | ||
| Curtis Lockshin | Phio Pharmaceuticals Corp | 55 | |
| Paul Dorman | Phio Pharmaceuticals Corp | 78 | |
| Jonathan Freeman | Phio Pharmaceuticals Corp | N/A | |
| Geert Cauwenbergh | Phio Pharmaceuticals Corp | 64 | |
| Keith Brownlie | Phio Pharmaceuticals Corp | 65 | |
| Mark Ternouth | Virax Biolabs Group | 56 | |
Management Performance
| Return On Equity | -4.1 | |||
| Return On Asset | -0.93 |
OncoSec Medical Leadership Team
Elected by the shareholders, the OncoSec Medical's board of directors comprises two types of representatives: OncoSec Medical inside directors who are chosen from within the company, and outside directors, selected externally and held independent of OncoSec. The board's role is to monitor OncoSec Medical's management team and ensure that shareholders' interests are well served. OncoSec Medical's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, OncoSec Medical's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Avtar Dhillon, Independent Chairman of the Board | ||
| Joon Kim, Director | ||
| Robert CPA, VP Controller | ||
| David Meininger, Senior Vice President - Business Development | ||
| Sheela MohanPeterson, Chief Legal and Compliance Officer | ||
| Robert Arch, CEO Pres | ||
| Tu MSc, VP Operations | ||
| Robert Pierce, Chief Medical Officer, Vice President - Research & Development | ||
| Sara Bonstein, CFO, COO | ||
| Mai MD, Consultant | ||
| Punit Dhillon, Co-Founder, CEO and President and Director | ||
| James DeMesa, Independent Director | ||
| Kim Jaffe, Assistant Operations | ||
| CPA CFA, Exec CFO | ||
| Annalisa Jenkins, Independent Director | ||
| Margaret Dalesandro, Director | ||
| Richard Slansky, CFO | ||
| Sharron Gargosky, Chief Clinical and Regulatory Officer | ||
| Daniel OConnor, Director | ||
| Robert Ward, Independent Director | ||
| Anthony Maida, Independent Director | ||
| Gregory Mayes, Director | ||
| Sandra Aung, Sr Officer |
OncoSec Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is OncoSec Medical a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -4.1 | |||
| Return On Asset | -0.93 | |||
| Current Valuation | 5.6 M | |||
| Shares Outstanding | 5.96 M | |||
| Shares Owned By Insiders | 28.01 % | |||
| Shares Owned By Institutions | 5.83 % | |||
| Number Of Shares Shorted | 192.06 K | |||
| Price To Earning | (3.12) X | |||
| Price To Book | 0.78 X | |||
| EBITDA | (35.92 M) |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in main economic indicators. Note that the OncoSec Medical information on this page should be used as a complementary analysis to other OncoSec Medical's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Analyst Advice module to analyst recommendations and target price estimates broken down by several categories.
Other Consideration for investing in OncoSec Stock
If you are still planning to invest in OncoSec Medical check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the OncoSec Medical's history and understand the potential risks before investing.
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years |